For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Scope of the Report:
This report studies the Duchenne Muscular Dystrophy Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Duchenne Muscular Dystrophy Therapeutics market by product type and applications/end industries.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
The global Duchenne Muscular Dystrophy Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Duchenne Muscular Dystrophy Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Bristol-Myers Squibb
- FibroGen (U.S.)
- Italfarmaco (Italy)
- NS Pharma (U.S.)
- PTC Therapeutics (U.S.)
- ReveraGen BioPharma (U.S.)
- Santhera Pharmaceuticals (Switzerland)
- Sarepta Therapeutics (U.S.)
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Pain Management Drugs
Market Segment by Applications, can be divided into
- Home Care Settings